| Literature DB >> 25228069 |
Jacob I Ayers1, Susan Fromholt1, Olga Sinyavskaya1, Zoe Siemienski1, Awilda M Rosario1, Andrew Li1, Keith W Crosby1, Pedro E Cruz1, Nadia M DiNunno1, Christopher Janus1, Carolina Ceballos-Diaz1, David R Borchelt1, Todd E Golde1, Paramita Chakrabarty1, Yona Levites1.
Abstract
The architecture of the spinal cord makes efficient delivery of recombinant adeno-associated virus (rAAV) vectors throughout the neuraxis challenging. We describe a paradigm in which small amounts of virus delivered intraspinally to newborn mice result in robust rAAV-mediated transgene expression in the spinal cord. We compared the efficacy of rAAV2/1, 2/5, 2/8, and 2/9 encoding EGFP delivered to the hindlimb muscle (IM), cisterna magna (ICM), or lumbar spinal cord (IS) of neonatal pups. IS injection of all four capsids resulted in robust transduction of the spinal cord with rAAV2/5, 2/8, and 2/9 vectors appearing to be transported to brain. ICM injection resulted in widespread expression of EGFP in the brain, and upper spinal cord. IM injection resulted in robust muscle expression, with only rAAV2/8 and 2/9 transducing spinal motor and sensory neurons. As proof of concept, we use the IS paradigm to express murine Interleukin (IL)-10 in the spinal cord of the SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis. We show that expression of IL-10 in the spinal axis of SOD1-G93A mice altered the immune milieu and significantly prolonged survival. These data establish an efficient paradigm for somatic transgene delivery of therapeutic biologics to the spinal cord of mice.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25228069 PMCID: PMC4426802 DOI: 10.1038/mt.2014.180
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454